What is LL-37?
LL-37 is a naturally occurring human antimicrobial peptide consisting of 37 amino acids. It is produced from the larger precursor protein hCAP18 and is an important component of the innate immune system, particularly at surfaces exposed to microorganisms.
The peptide is produced by several cell types, including neutrophils and epithelial cells. Research into LL-37 extends beyond direct antimicrobial activity and includes immune signalling, inflammation, microbial interactions, biofilm biology and cellular responses associated with tissue injury.
Cathelicidins and the CAMP gene
LL-37 belongs to the cathelicidin family of antimicrobial peptides. In humans, the CAMP gene encodes the precursor protein hCAP18, which can subsequently be processed by enzymes to release biologically active LL-37.
Unlike some species that possess several cathelicidin genes, humans have one recognised cathelicidin gene. Regulation of CAMP expression and processing of hCAP18 are therefore important areas of research into how LL-37 participates in host defence and inflammatory responses.
Antimicrobial-peptide biology
Antimicrobial peptides form part of the body's first-line defence against microorganisms. Many, including LL-37, possess a positive electrical charge that can facilitate interactions with negatively charged components of microbial membranes.
LL-37 can adopt an alpha-helical structure and has demonstrated membrane-disrupting activity against certain microorganisms under laboratory conditions. However, its behaviour is strongly influenced by factors including concentration, pH, salt concentration and the surrounding biological environment.
This means antimicrobial activity demonstrated in a controlled laboratory experiment cannot automatically be assumed to occur in the same way within living organisms.
Innate immunity
Innate immunity provides rapid biological defence without requiring the highly specific recognition mechanisms characteristic of adaptive immunity. LL-37 is produced at barrier surfaces including the skin, respiratory tract and gastrointestinal system and can also be released by immune cells.
In addition to interacting directly with microorganisms, LL-37 has been investigated for effects on immune-cell recruitment, cytokine signalling and communication between different components of the immune system.
For this reason, LL-37 is increasingly studied as an immunomodulatory molecule rather than simply as a naturally occurring antimicrobial substance.
Bacterial, viral and biofilm research
Laboratory studies have demonstrated LL-37 activity against various Gram-positive and Gram-negative bacteria. Proposed mechanisms include interactions with microbial membranes and disruption of membrane integrity.
Research has also investigated LL-37 in experimental models involving viruses and fungi, although the mechanisms and strength of evidence vary considerably between organisms.
Biofilms represent another important research area. These structured microbial communities can behave very differently from free-living microorganisms. Experimental studies have examined whether LL-37 can influence biofilm formation, bacterial attachment and microbial behaviour within biofilm environments.
Inflammatory signalling
LL-37 interacts with several cellular signalling pathways and has been investigated for effects on cytokine production, chemotaxis and immune-cell activation.
Its biological behaviour is highly dependent on context. Under some experimental conditions LL-37 can modify or suppress particular inflammatory signals, while under others it can contribute to signalling associated with inflammation.
It is therefore more accurate to describe LL-37 as an immunomodulatory peptide than to classify it simply as either anti-inflammatory or pro-inflammatory.
Wound biology
LL-37 is naturally present in skin and has been detected in biological environments associated with tissue injury. Research has investigated its interactions with keratinocytes, fibroblasts, endothelial cells and immune cells involved in normal responses to damaged tissue.
Experimental studies have also examined processes including cell migration, epithelial responses and formation of new blood vessels. These observations help researchers investigate the biological role of endogenous LL-37 during tissue repair.
However, evidence that naturally produced LL-37 participates in wound biology does not by itself demonstrate that externally supplied LL-37 can improve wound healing in humans.
Potential pro-inflammatory effects
LL-37's involvement in host defence does not mean that greater LL-37 activity is always beneficial. Abnormal expression or regulation of the peptide has been investigated in several inflammatory and autoimmune conditions.
One particularly interesting mechanism involves interactions between LL-37 and nucleic acids. Under certain experimental conditions, LL-37 can form complexes with DNA or RNA and influence their recognition by immune receptors, potentially contributing to inflammatory signalling.
This illustrates the context-dependent nature of LL-37 biology: a molecule involved in protective innate immunity can also participate in inappropriate immune activation under particular circumstances.
Evidence limitations
Much of the mechanistic evidence surrounding LL-37 comes from in-vitro experiments and animal models. These studies are valuable for understanding antimicrobial mechanisms and immune signalling, but laboratory conditions differ substantially from the complex biological environment present in humans.
Another important distinction is between endogenous and externally supplied LL-37. Demonstrating that naturally produced LL-37 has a physiological function does not establish that administering synthetic LL-37 recreates that function or produces a clinical benefit.
Research should therefore be interpreted according to the precise peptide preparation, concentration, experimental model, microorganism or cell type and endpoint investigated.
Frequently asked questions
What does LL-37 mean?
The name reflects the mature peptide beginning with two leucine residues, represented by “LL”, and its total length of 37 amino acids.
Is LL-37 naturally produced by humans?
Yes. LL-37 is the principal human cathelicidin antimicrobial peptide and is generated through processing of the hCAP18 precursor encoded by the CAMP gene.
Is LL-37 an antibiotic?
Not in the conventional pharmaceutical sense. LL-37 is an endogenous antimicrobial peptide capable of interacting with certain microorganisms under experimental conditions. This is different from being an approved antibiotic medicine.
Does LL-37 only interact with bacteria?
No. Research involving LL-37 includes bacteria, viruses, fungi, biofilms, immune cells and numerous cellular signalling pathways.
Is LL-37 anti-inflammatory?
Not simply. LL-37 can influence inflammatory signalling in different directions depending on the biological environment. Immunomodulatory is therefore a more accurate description.
Why is LL-37 studied in wound biology?
Endogenous LL-37 occurs in skin and has been investigated in relation to epithelial cells, immune responses, cell migration and other processes associated with tissue repair.
Can laboratory antimicrobial results be applied directly to humans?
No. Activity demonstrated against microorganisms under controlled laboratory conditions does not establish that the same effect will occur safely or effectively in humans.
Scientific references
Scientific literature on LL-37 includes research into the CAMP gene, cathelicidin processing, antimicrobial mechanisms, innate immunity, biofilms, inflammatory signalling and tissue biology. Evidence should be separated according to whether studies examine endogenous LL-37, synthetic peptide preparations, isolated cells, microorganisms, animal models or human biology.